You are on page 1of 21

TIPS 1334 No.

of Pages 21


Voltage-Gated Ion Channels

in the PNS: Novel Therapies
for Neuropathic Pain?
Gareth R. Tibbs,1 David J. Posson,1 and Peter A. Goldstein1,2,*
Neuropathic pain arises from injury to the nervous system. Conditions associated with neuropathic pain are diverse, and lesions and/or pathological changes
in the central nervous system (CNS) or peripheral nervous system (PNS) can
frequently, but not always, be identied. It is difcult to treat, with patients often
on multiple, different classes of medications, all with appreciable adverse side
effect proles. Consequently, there is a pressing need for the development of
new medications. The development of such therapeutics is predicated on a
clear understanding of the relevant molecular and cellular processes that
contribute to the development, and maintenance, of the neuropathic pain state.
One proposed mechanism thought to contribute to the ontogeny of neuropathic
pain is altered expression, trafcking, and functioning of ion channels
expressed by primary sensory neurons. Here, we will focus on three voltagegated ion channel families, CaV, HCN, and NaV, rst reviewing the preclinical
data and then the human data where it exists.
Neuropathic Pain
As dened by the International Association for the Study of Paini [1], pain is an unpleasant
sensory and emotional experience associated with actual or potential tissue damage; chronic
pain is pain that persists beyond the normal tissue healing time (usually 3 months); neuropathic
pain is pain caused by a lesion of, or damage to, the somatosensory nervous system (Figure 1A).
Chronic pain greatly impairs an individual's quality of life, is widely prevalent, and has signicant
cost. In the USA alone, at least 116 million adults suffer from chronic pain; the associated costs
exceed $500 billion/year [2]. Neuropathic pain accounts for 18% of patients with chronic pain.
Despite limited efcacy, opioid pain relievers (OPRs) are routinely prescribed for chronic pain; in
2012, 240 million prescriptions were written for OPRs in the USA (a 33% increase from 2001),
with a direct cost of $8.34 billion, a 110% increase over the same period [3]. Signicant risks
are involved with this therapy, including physical dependence, addiction, and fatal poisoning [4].
In the USA, approximately half of all deaths from drug overdose are attributable to prescription
drugs, with opioid painkillers accounting for the vast majority of these (71%) [5]. However, the
problem of misuse/abuse is worldwide [610].
The bitter irony is that there are no convincing data that oxycodone (the opiate base for
drugs such as Percocet and Oxycontin) has any value in treating patients with neuropathic
pain, including that associated with diabetic neuropathy, postherpetic neuralgia, or other
neuropathic pain conditions [11]. Similarly, there is no compelling evidence of efcacy for
the use of buprenorphine (a thebaine derivative opioid that acts as an agonist at m-opioid
and ORL-1 receptors, whereas it is an antagonist at k- and d-opioid receptors) in treating
neuropathic pain [12].

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

Neuropathic pain results from injury to
the central and/or peripheral nervous
system. Such injury can result in neuronal excitability, the basis of which
includes altered expression, trafcking,
and functioning of ion channels
expressed by primary sensory neurons,
including CaV, HCN, and NaV channels.
Extensive pharmacological data indicate
that it is possible to synthesize novel
chemical entities (NCEs) that selectively
inhibit channel function within each
channel family. In preclinical tests, NCEs
that selectively target CaV, HCN, and
NaV channels have all demonstrated efcacy in various models of neuropathic
pain; replicating those results in humans
has been difcult, but NaV blockers (at
least) show promise.
Improvements in animal and human
testing methodologies are needed to
identify and develop safe and effective
NCEs as antihyperalgesics.

Department of Anesthesiology, Weill
Cornell Medical College, New York,
Department of Medicine, Weill Cornell
Medical College, New York, NY, USA

(P.A. Goldstein).
2016 Elsevier Ltd. All rights reserved.

TIPS 1334 No. of Pages 21

Neuropathic pain syndromes represent a heterogeneous collection of conditions that can be

broadly grouped into the following categories: (i) central nervous system (CNS) lesions, (ii)
complex neuropathic disorders, (iii) peripheral nervous system (PNS) focal and multifocal lesions,
and (iv) PNS system generalized polyneuropathies [13]. Within each group, multiple distinct
conditions exist, and the underlying pathways leading to the common phenotypic feature (pain)
are often variable [1416]. Consequently, to cover the entire spectrum of potential neuropathic
pain treatments is beyond the scope of this review. However, commonalities do exist; one such
common pathway is characterized by neuronal hyperexcitability and spontaneous activity [17];
such behavior can arise from several distinct processes, including altered expression, trafcking,
and functioning of ion channels expressed by primary sensory neurons [15]. In turn, the resulting
hyperexcitability may underlie the sensory abnormalities associated with neuropathic pain
(allodynia, hyperalgesia, spontaneous pain). As will be discussed later, changes in ion channel
expression and function at the level of the primary afferent can be seen in distinct animal models
of neuropathic pain, including that induced by peripheral nerve injury, diabetes, and exposure to
chemotherapeutics, all of which are common etiologies of neuropathic pain in the human
population [13]. While many channels contribute to the electrophysiological properties of
neurons (Figure 1B), there is strong preclinical evidence implicating the involvement of three
voltage-gated ion channel families in particularCaV, HCN, and NaVall of which are fundamentally involved in regulating neuronal excitability. Consequently, ion channel-driven hyperexcitability in sensory neurons presents the unifying theme for this review, and we will rst examine the
preclinical data connecting CaV, HCN, and NaV channels to neuropathic pain and then the
human data where it exists.

Potential Therapeutic Targets

CaV Channels
Voltage-gated Ca2+ channels (CaV) are broadly classied into three closely related groups based
on genes coding the obligatory pore-forming / subunit: CaV1, CaV2, and CaV3 [18,19] (Figure 2).
Three genes comprise the CaV3 subfamily (Figure 2A), and these channels give rise to the lowvoltage activated (LVA) T-type current. T-type Ca2+ currents are present in dorsal root ganglia
(DRG) neurons [2023], the basis of which is CaV3.2 and CaV3.3, at least in small- and mediumsized sensory neurons [2426], including those that are IB4 positive [27,28], a carbohydrate
marker for non-peptidergic nociceptors. This expression pattern suggests that CaV3 channels
might contribute to nociceptive sensory processing [29] and, as such, might also hold the
potential for therapeutic targeting.
CaV3 channels were rst shown to contribute to neuropathic pain by Slobodan Todorovic and
colleagues who demonstrated that mibefradil (a T-type CaV channel antagonist [18,30]) could
block the thermal hyperalgesia produced by intradermal injection of either dithiothreitol or
L-cysteine, reducing agents that augment heterologously expressed CaV3.2 channel and T-type
currents in DRG neurons [31]. Subsequent work by Bourinet et al. showed that antisense targeting
of CaV3.2 induced a signicant decrease in the expression of CaV3.2 mRNA and protein expression as well as a large reduction in CaV3.2-dependent T-type currents in nociceptive DRG neurons.
In normal and neuropathic (chronic constriction injury model; CCI) rats, the CaV3.2, but not CaV3.1
or CaV3.3, antisense treatment resulted in major antinociceptive, antihyperalgesic, and antiallodynic effects, suggesting that CaV3.2 plays an important function in sensory transduction in acute
and neuropathic pain states [32]. In the Bennet CCI model, it was shown that T-type current density
increases in response to chronic constriction injury of the sciatic nerve [33], and this observation
was conrmed by Yue and colleagues, who observed an increase in T-current density and
amplitude following spinal nerve ligation; these changes were accompanied by increases in mRNA
levels for both CaV3.2 and CaV3.3 (note that a similar upregulation in CaV3.2, but not CaV3.1 or
CaV3.3, mRNA occurs in a carrageenaninammatory model [34]) as well as a neuropathic
phenotype that could be relieved by mibefradil [35] (and see also [36]).

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21






Dorsal root
Spinal cord



Excitatory inputs


Acon potenals
Kv3 throughout dendrite






Inhibitory inputs


Nodes of ranvier
Nav, KCNQ, Kv3.1b

Figure 1. Schematic Displaying General Sites of Origin of Neuropathic Pain. (A) Neuropathic pain arises from injury
to neurons in the peripheral and/or central nervous system. Amplication of signals arising in primary afferents can result
from several distinct processes, including altered expression and trafcking of receptors and ion channels as well as from
changes in ion channel threshold and kinetics. Such changes can lead to increased spontaneous activity (i.e., action
potential ring) and/or cellular responsiveness to sensory stimuli. (B) General localization of voltage-gated ion channels in a
model neuron. In general, NaV channels are found in the axon initial segment (AIS), nodes of Ranvier, and presynaptic
terminals. KV1 is found at the juxtaparanodes (JXPs) in adult myelinated axons and presynaptic terminals. The KV channel
KCNQ is found at the AIS and nodes of Ranvier, and KV3.1b is also found at the nodes of Ranvier. Excitatory and inhibitory
inputs (EPSPs and IPSPsexcitatory and inhibitory postsynaptic potentials; yellow and blue presynaptic nerve terminals,
respectively) from the somatodendritic region spread passively to the AIS, the site of action potential (AP) generation; APs
propagate to the presynaptic axon terminals to activate voltage-gated Ca2+ (CaV2.2) channels, thereby increasing
intracellular Ca2+ levels that trigger vesicle fusion and exocytosis. Hyperpolarization-activated cyclic nucleotide-gated
(HCN) channels have a gradient distribution that increases in density from the soma to the distal dendrites (dark blue
shading); the variable and highly localized distribution of HCN channels allows them to participate in setting resting
membrane potential, input resistance, and dendritic integration of synaptic signals. KV2.1 is found in clusters on the soma
and proximal dendrites (light yellow ovals). KV3 is found throughout the dendrite, while KV4.2 is located more prominently on
distal dendrites (light blue shading). Dendritic CaV channels increase in density toward the proximal dendrites and the soma.
(Image and legend adapted, with permission, from [228].).

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21








Cav3.1 (CACNA1G)
Cav3.2 (CACNA1H)
Cav3.3 (CACNA1I)





Cav2.1 (CACNA1A)
Cav2.2 (CACNA1B)
Cav2.3 (CACNA1E)




Cav1.1 (CACNA1S)
Cav1.2 (CACNA1C)
Cav1.3 (CACNA1D)
Cav1.4 (CACNA1F)




Amino acid sequence identy (%)



EC loop I

Domain: I




+H N



+H N










Pore domain


Figure 2. CaV Channel Family Tree and Structural Architecture. (A) Sequence similarity of voltage-gated calcium channel /1 subunits. Phylogenetic
representation of the primary sequences of CaV channels. Only the membrane-spanning segments and pore loops (350 amino acids) are compared. Gene names
are shown to the right of the protein name along with the original current descriptors. L-, P/Q-, N-, and R-type currents are classied as high voltage activated (HVA),
whereas T-type currents are low voltage activated (LVA). (B) Subunit structure of CaV channels. Predicted / helices are depicted as cylinders. The lengths of lines
correspond approximately to the lengths of the polypeptide segments represented. (C) Overall architecture of the rabbit CaV1.1 complex. The overall electron microscopy
(EM) density map (left) and structure (right) of the rabbit CaV1.1 complex. The density corresponding to the b subunit was generated from the 6.1 map at a contour level
of 0.0135, and the other regions were from the 4.2 map at a contour level of 0.0435. (D) Ribbon representation (side view) of the CaV3.1 homology structure model with
the ab initio extracellular loop (EC loop 1) connecting IS5IP shown on top (gray, surface representation). Domains IIV (S1S6) are labeled as shown. Extracellular
cysteines are shown as spheres. (A, B, and legends) Modied, with permission, from [18]. (C and legend) Modied, with permission, from [229]. (D and legend) Modied,
with permission, from [230].

In addition to nerve injury-induced neuropathic pain, CaV3 channels contribute to painful diabetic
neuropathy (PDN) [37]. Yusaf et al. demonstrated that streptozocin (STZ)-induced diabetes
increased CaV3.1 mRNA expression in medium- to large-sized DRG neurons and CaV3.3 mRNA
expression in small- to medium-sized cells [38], while Cao et al. demonstrated that STZ
treatment increased CaV3.2 mRNA levels [39]. Consistent with those observations, electrophysiological studies found that STZ treatment increased T-current density and peak amplitude
[27,40], and the pharmacological prole of those currents strongly suggested that the observed
effects resulted from an increase in CaV3.2 channel expression [27]. Using a similar approach as
Bourinet et al., Messinger and colleagues used the STZ diabetic rat model to study the effects of
antisense oligonucleotide suppression of CaV3.2 expression. They found that downregulation
of CaV3.2 channel expression had a profound antihyperalgesic effect in diabetic rats that was

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

accompanied by a signicant decrease in T-type Ca2+[9_TD$IF] currents in DRG neurons while glycemic
control with daily insulin injections reversed the observed effects both in vivo and in vitro. These
observations lend further credence to the idea that CaV3.2 channels contribute to the cellular
hyperexcitability underlying the development of PDN [41].
Leptin-decient (ob/ob) mice are genetically predisposed to developing diabetes and PDN
[42,43]. In vitro, small DRG neurons from ob/ob mice demonstrate a developmentally transient
increase in T-type Ca2+ current density, which is accompanied by persistent thermal and
mechanical hypersensitivity in vivo [44]; the hypersensitivity was relieved by the neuroactive
steroid and selective T-channel antagonist, (3b,5/,17b)-17-hydroxyestrane-3-carbonitrile
(ECN) [45]; mice lacking CaV3.2 did not develop STZ-induced thermal or mechanical hypersensitivity and ECN had no effect on paw withdrawal latency [44].
Thus, there is compelling evidence indicating that CaV3 antagonists might have therapeutic
value as antihyperalgesics for the relief of PDN and/or neuropathic pain following nerve injury.
Recent work with distinct molecular classes of CaV3 channel blockers has shown preclinical
promise (Table 1). Other approaches to suppressing T-type currents, and relieving neuropathic pain, include deglycosylation of CaV3.2 channels with neuraminidase [46] and inhibition of CaV3.2 activity by enhancing ubiquitination due to inhibition of the deubiquitinating
enzyme, USP5 [47].

Table 1. Recent Preclinical Trials with CaV3 Channel Blockers









Inammatory painintradermal
Neuropathic streptozocininduced diabetesthermal





Acute nociceptionmechanical
and thermal sensitivity
Neuropathic painbutyrate
enema-induced colonic


Compound 9

N-Alkylated carbazole-3carboxylic derivative


Neuropathic painpartial
sciatic nerve injurymechanical
Inammatory painintraplantar





Neuropathic painspinal nerve

ligation, sciatic nerve chronic
constriction injury, and
Monoiodoacetic acid-induced
knee joint pain model
Capsaicin secondary


Compound 7b



Neuropathic painspinal nerve

ligationmechanical and
thermal hypersensitivity


Compound 10b



Neuropathic painspinal nerve

ligationmechanical and
thermal hypersensitivity


Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

But what is true in rodent (or other animal) models is not necessarily true in humans [48]. Thus,
orally administered ABT-639 (which was shown to produce dose-dependent analgesia in a rat
model of knee joint pain and antihyperalgesia in peripheral nerve injury, chemotherapy- and
capsaicin-induced rat neuropathic pain models [49]) failed to suppress C-ber activity [50] or to
improve self-reported pain scores in prospective, randomized, double-blind controlled trials
of subjects with PDN [50,51]. The failure of ABT-639 to demonstrate any meaningful efcacy led
the authors to state that the data [do] not support T-type calcium channel CaV3.2 as a potential
target for treating diabetic neuropathic pain [51]. Based on positive results in a human
experimental pain model [52] obtained with a less selective and more CNS-penetrant T-type
Ca2+[10_TD$IF] blocker (Z944) [53], however, the authors nal conclusion was that targeting of T-type
calcium channel blockers for the treatment of chronic pain should not be discarded without
further investigation.
So where does this apparent contradiction leave us? Is this an issue of potency, selectivity, site of
action, or something else? In the study by Ziegler el al. [51], 100 mg of ABT-639 was orally
administered to patients every 12 h, resulting in weekly mean plasma levels ranging from 1313 to
2932 ng/ml (2.96.4 mM), which were in the range of the Cmax and Ctrough levels previously
reported in humans on the same dose schedule [54]. More important, the reported plasma
concentrations were commensurate with the IC50 values for T-type currents in rat DRG neurons
(8 mM) and heterologously expressed human CaV3.2 channels (2 mM) [49]. Thus, it is unlikely that
insufcient drug plasma levels were the source of the negative results, and whether a more
potent CaV3.2 blocker would have demonstrated efcacy is unclear. An important limitation of
the study, however, was that it was only 6 weeks in duration, which may have been too short to
detect efcacy. If preclinical efcacy was solely a function of ABT-639-mediated suppression
of CaV3.2-driven hyperexcitability in DRG neurons, then comparable efcacy should have been
observed in humans as steady-state plasma levels are observed by day 5 of a twice daily dose
regimen [54]. But as noted earlier, pain, including neuropathic pain, has an important supraspinal, affective component. Thus, inhibition of CaV channels on central neurons might contribute to the antihyperalgesic effect reported for Z944, and such central efcacy certainly would not
preclude an effect on CaV channels present in peripheral neurons. But what about something
else? Changes in connectivity between the default mode and salience (which includes the
prefrontal cortex) networks have been demonstrated in subjects with numerous chronic pain
states [5557]. The maladaptive plasticity seen in chronic pain can be thought of as one type
of learned behavior [58], which is consolidated over time, implying that its erasure, or reversal,
will also require time; how much time is unknown, but if it is proportional to the time required to
learn the behavior, then short-term assessment, as in the study by Ziegler et al., will fail to detect
drug efcacy in the face of long-term acquisition and consolidation. Thus, additional long-term
studies are needed [1_TD$IF]with [12_TD$IF]ABT-639, and other CaV3.2 antagonists, before abandoning them as
potential antihyperalgesics.
The study by Ziegler and colleagues used multiple, validated, pain assessment tools, including
the Neuropathic Pain Symptom Inventory total intensity score, which included questions that
explore both spontaneous and evoked pain symptoms. However, the study could not demonstrate human in vivo target engagement as there are no validated molecular biomarkers for pain,
and it did not utilize functional magnetic resonance imaging (fMRI), which may have been able to
detect early changes in brain circuits involved in pain perception. fMRI has been used to correlate
the effects of subject expectation on the analgesic efcacy of a m-opiate receptor agonist
(remifentanil) with changes in activity in the underlying neural circuitry; based on those results, the
argument was made that an individual's expectation of a drug's effect critically inuences its
therapeutic efcacy and that regulatory brain mechanisms differ as a function of expectancy. . . it
may be necessary to integrate patients beliefs and expectations into drug treatment regimens
alongside traditional considerations in order to optimize treatment outcomes [59]. Whether that

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

argument supports Ziegler et al.s nal contention that we should not discard T-type calcium
channel blockers for the treatment of chronic pain without further investigation [51] remains to
be seen. Demonstration of an effect on an imaging signal may be difcult to reconcile with a
patient's report of no relief from a given intervention since pain is by denition a subjective
experience. That caveat notwithstanding, imaging studies are likely to be incorporated into future
clinical trials barring the advent of other validated biomarkers [6062].
It is worth briey mentioning CaV2.2 channels as therapeutic targets for the treatment of
neuropathic pain. mRNA coding for CaV2.2 is present in DRG neurons [63] as is the corresponding high-voltage activated N-type current [6466]. In vitro, CaV2.2-generated currents
are potently inhibited by the Conus snail toxin -conotoxinGVIA [6769], and in acutely
prepared rat spinal cord slices, block of CaV2.2 reduced Ad ber-evoked transmitter release
(presumably due to inhibition of Ca2+ inux into the axon terminal), as well as the magnitude of
depolarization-evoked Ca2+ transients in Lamina I neurons [70]. In vivo, inhibition of CaV2.2
channels by -conotoxinGVIA [71] or synthetic conotoxin derivatives SNX111, SNX159, or
SNX239 [72] was shown to relieve mechanical and cold allodynia in rat models of neuropathic
pain. These, and other results, led to the development, and introduction into clinical practice, of
the synthetic CaV2.2 channel blocker ziconotide (Prialt; Elan Pharmaceuticals, San Diego, CA,
USA) for the treatment of severe chronic pain not relieved by systemic analgesics, adjunctive
therapies, or intrathecal morphine [73]; although effective, ziconotide has limited widespread use
due to the requirement for intrathecal administration coupled with serious neurological and
psychiatric related adverse events. Despite the poor riskbenet prole, efforts have continued
at developing novel chemical entities (NCEs) that target CaV2.2 on the assumption that the
adverse side effects are drug, rather than class, specic. One strategy has been to develop orally
active tetrahydroisoquinoline derivatives that are CaV2.2 selective; such agents do not inhibit
cytochrome P450 activity and have shown antihyperalgesic efcacy in rat spinal nerve ligation
models without overt CNS toxicity, making them plausible candidates for further development
[74,75]. In a break from the highly selective, one target tradition, attempts to develop multitarget
bifunctional molecules with agonist activity for m-opiate receptors and blocking activity for
CaV2.2 have been undertaken [76]; in vivo, such molecules are weakly analgesic, and the
analgesia appears to result from m-opiate receptor activation rather than CaV2.2 inhibition. Given
that multiple pathways contribute to neuropathic pain, the development of bifunctional ligands
certainly has appeal; given the signicant risks associated with opiate analgesics, however,
designing a drug that includes m-opiate receptor agonist activity may not be desirable.
HCN Channels
Hyperpolarization-activated cyclic nucleotide (HCN)-gated ion channels are members of the KV
superfamily that are weakly selective for K+ over Na+ and are activated by membrane hyperpolarization, not depolarization [77,78]. Four mammalian genes have been identied, each
coding for a single channel isoform (HCN14; Figure 3), which are the basis of the neuronal
pacemaker current, Ih [7983]. HCN channels assemble as homotetramers and heterotetramers
with only the HCN2/HCN3 combination disfavored [8488].
Originally described as a current, If, responsible for the phase 4 spontaneous depolarization that
precedes the cardiac action potential [89], Ih (synonymous with If) is now known to regulate
rhythmic and subthreshold excitability throughout the PNS and CNS by controlling the resting
membrane potential, input resistance, and synaptic integration [78,90,91]. HCN14 channels
are variably expressed throughout the nervous system [92,93]. In large and medium diameter
(Ab) cutaneous primary sensory neurons, HCN1 and HCN2 expression dominates while HCN3
is low and HCN4 minimal; in smaller cells (Ad, C), HCN1 is robust in subsets of C-ber
nociceptors (both IB4+ and IB4) and noxious cold-sensing neurons [9496]. Importantly, with
regard to drug development, HCN4 is the predominant HCN isoform expressed in the human

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21


Pore domain


mHCN2 (mHcn2)
mHCN4 (mHcn4)
mHCN1 (mHcn1)
mHCN3 (mHcn3)


Amino acid sequence dierences (%)




K /Na



2 1








Figure 3. HCN Channel Family Tree and Structural Architecture. (A) Phylogenetic tree deduced from sequence
analysis for the amino acid sequences for murine (m)HCN14, SPIH (Strongylocentrotus purpuratus), and HVIH (Heliothis
virescens) proteins. (B) HCN channels are tetramers (inset). One monomer is composed of six transmembrane segments
including the voltage sensor (S4) and the pore region formed of S5 and S6 and the intervening loop. The pore region
contains the selectivity lter carrying the GYG motif. The carboxy terminal channel domain is composed of the C-linker and
the cyclic nucleotide-binding domain (CNBD). The C-linker consists of six /-helices, designated A0 to F0 . The CNBD follows
the C-linker domain and consists of four /-helices (AC and P) with a b-roll (incorporating the P-helix, P not shown in the
cartoon) between the A- and B-helices (thick gray line). Human mutations involved in Ih channelopathies are indicated as
gray circles. (C and D) Homology model of human HCN1 based on X-ray crystal structures of K+ channels and the HCN2
cytoplasmic domain, built using the program Modeller [235]. The structural templates were PDB 2R9R [236] (VSDs, green),
3BEH [237] (pore, blue), and 1Q5O [238] (C-linkerCNBD, grey). The modeled S4S5 linker is highlighted (red). Side (C) and
top (D) views were generated in PyMOL. (A and legend) Modied, with permission, from [239]. (B and legend) Modied, with
permission, from [77].

heart [97,98], especially in the sinoatrial node, where the HCN4/HCN1 mRNA ratio is 7 [99] (but
see [100]). HCN2 is present but there is little or no HCN1 or HCN3 [77,78,101]. The expression
prole suggests that therapeutic targeting of Ih in the PNS may be best achieved with antagonists selective for HCN1 and/or HCN3 [101].
Animal models of peripheral nerve injury demonstrate hyperalgesia and allodynia [102,103].
Injured DRG neurons show increased spontaneous rhythmic electrical activity [104106], and
this increased activity is Ih-dependent [107109]. In peripheral nerve injury models of neuropathic pain, there is an increase in HCN expression in sensory neurons that is more pronounced
for HCN1 than for HCN2 [109], and HCN subunit trafcking is altered [108110], with accumulation of channel protein in the axon rather than the soma [109]. Increased expression is
accompanied by increased Ih amplitude [108,111113] and sensory cell hyperexcitability

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

[108,112114], both of which are inhibited by superfusion with the HCN channel blocker
ZD7288 [107109,111,115]. Spontaneous activity in the sciatic nerve ipsilateral, but not
contralateral, to the injury is Ih-dependent [109], and low-dose intraperitoneal administration
of ZD7288 alleviates mechanical allodynia [108,115,116]. Those results strongly suggest that
HCN channels expressed on sensory neurons are the primary site of action for ZD7288 but
variability in efcacy (possibly due to drug pharmacokinetics) following proximal (perineural) or
distal (intraplantar) injection precludes exact anatomic localization of the site of analgesic activity
of ZD7288 [108,109,116,117].
Increases in HCN expression in sensory neurons are not limited to those seen following direct
nerve injury. In the STZ diabetic rat model, HCN1 and HCN3 channel proteins were overexpressed in A-ber nodose ganglion neurons, while HCN2 and HCN3 channel proteins were
overexpressed in C-ber neurons, and the increase in channel expression was accompanied by
a corresponding increase in Ih in both cell types [118]. Similarly, exposure to the antineoplastics
oxaliplatin [119] or paclitaxel [120], both of which are associated with chemotherapy-induced
neuropathic pain [121,122], increased HCN1 mRNA expression and paclitaxel increased
excitability of lumbar DRG neurons [120].
Ivabradine is a selective HCN channel pore blocker that blocks all HCN isoforms and
native pacemaker currents in the low micromolar range (in vitro, the IC50 of ivabradine for
heterologously expressed HCN channels is 1 to 2.5 mM [123,124], which closely corresponds to the IC50 of 2.8 mM for native If in sinoatrial node cells [125]); it is clinically approved
throughout Europe and Asia (as Procoralan, Coralan, Corlentor, or Coraxan; Servier,
Suresnes, France) and the USA (as Corlanor; Amgen, Thousand Oaks, CA, USA) as a pure
bradycardic agent for the treatment of chronic angina pectoris and heart failure. In agreement
with the molecular, cellular, and behavioral data, ivabradine has been shown to be antihyperalgesic in multiple animal models (inammatory, nerve injury, chemotherapy induced)
of neuropathic pain [119,120,126]. At present, two trials are listed in the EU Clinical Trials
Register databaseii aimed at studying the effect of ivabradine on pain, one in healthy human
volunteers (EudraCT number: 2012-005627-32), and one in individuals with neuropathic
pain (EudraCT number: 2011-003933-32). As the dose required to produce antihyperalgesia
is essentially the same as that required to produce bradycardia (at least in rodents [126]), it
will be interesting to see if drug efcacy is limited by an unacceptable cardiovascular side
effect prole.
With regard to interpretation of the above clinical trials, it is worth commenting on the potency
with which ivabradine works clinically versus its effects on HCN channels. The initial dose
recommendation for ivabradine is 5 mg oral (p.o.) twice daily (BID). In human subjects, the
plasma concentration (Cmax) following a 5 or 10 mg p.o. dose is 9.7 and 16.3 ng/ml,
respectively, and the terminal half-life (t1/2) is 1.9 h [127,128]. In response to a 20 mg p.o.
BID dose, the human plasma concentration is 85  46 ng/ml at the end of a 5 day dose regimen,
and is essentially identical to the plasma concentration obtained with a single 20 mg oral
dose (83  31 ng/ml), suggesting that drug accumulation does not occur in response to
BID dose [129]. The bradycardic effect is dose-dependent [129,130] and can be detected
at dose regimens as low as 2.5 mg p.o. BID [130]. Effect onset is also rapid (occurs following
a single dose) [129] and reaches sustained efcacy at the end of 1 month [131]. That such a dose
regimen is associated with a physiologically detectable and relevant bradycardia is somewhat
surprising as the corresponding molar concentrations for the reported plasma levels are 19,
32, and 167 nM, concentrations that should elicit minimal inhibition of heterologously expressed
HCN channels and native If. If similarly modest suppression of Ih is sufcient to dampen
excitability in DRG neurons, signicant pain relief might be obtainable without the need to
completely suppress HCN function.

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

Our demonstration that the alkylphenols 2,6-di-tert-butyl-phenol (2,6-DTBP) and 2,6-di-isopropylphenol (propofol) impair HCN1 gating (in contrast to ivabradine, which is a pore blocker)
and ameliorate mechanical allodynia and thermal hyperalgesia [132] is consistent with alkylphenol-mediated suppression of excitability of HCN1/2 rich Ab mechanoreceptors and/or Ad or
C-type nociceptors. As alkylphenol-mediated inhibition of HCN1HCN2 heteromers is comparable to inhibition of HCN1 homomers [133], pharmacological targeting of sensory neuron Ih
channels containing the HCN1 isoform, alone or in combination with HCN2, may provide relief
for a wide range of painful peripheral neuropathies. As HCN4 is insensitive to relevant concentrations of 2,6-DTBP [132], we predict that 2,6-DTBP, or a suitably optimized congener, will
selectively target HCN1 and thus minimize or eliminate drug-induced bradycardia (the primary
cardiac effect of pan-HCN blockers such as ZD7288 and ivabradine [134137]). Furthermore,
unwanted CNS side effects may be avoided by restricting penetration of alkylphenol compounds
across the bloodbrain barrier.
NaV Channels
Voltage-gated sodium (NaV) channels are the basis of the Na+-dependent action potential in
excitable cells; as with CaV and HCN channels, there are multiple obligatory pore-forming
/ subunits (NaV1.11.9), each being a distinct gene product (Figure 4); coexpression with
one of four b subunits results in channels with altered biophysical properties [138]. Three
channelsNaV1.7, NaV1.8, and NaV1.9have garnered the most attention as potential therapeutic targets because gain-of-function mutations in these isoforms have been clearly linked
to neuropathic pain in humans [139142]. Gain-of-function mutations in NaV1.7 have been
identied in patients with inherited erythromelalgia [143147], an autosomal dominant condition characterized by burning pain and erythema of the extremities [148], as well as in small
ber neuropathy (also known as painful neuropathy) [149], which typically consists of
small ber related symptoms, including pain, autonomic dysfunction, loss of pinprick and
thermal sensation, allodynia, or hyperalgesia, but without evidence of large ber dysfunction
(i.e., muscle weakness, loss of light touch, and/or proprioceptive or vibratory sensation,
hyporeexia, or areexia) [150]. There is some evidence that gain-of-function mutations in
NaV1.7 may also contribute to PDN [151], but the mechanistic data supporting such a
contribution are more complicated than just a simple case of increased channel activation
[152]. Gain-of-function mutations in NaV1.8 [153155] and NaV1.9 [156,157] have also been
identied in patients with small ber neuropathy [153156] and familial episodic pain [157],
which is characterized by intense, relapsing pain primarily in the distal lower extremities (but
occasionally in the upper body, mostly in upper extremity joints) appearing late in the day,
diaphoresis, and pain relief with oral anti-inammatory analgesics. The gain-of-function
mutations result in numerous changes in channel gating (e.g., depolarized slow and fast
inactivation, impaired slow inactivation, hyperpolarized activation, enhanced recovery from
fast inactivation, slowed deactivation), the net result being hyperexcitability of DRG neurons
[140]. Interestingly, however, one gain-of-function mutationNaV1.9Leu811Prois associated
with congenital insensitivity to pain in humans, likely due to inactivation of other Na+ and Ca2+
currents contributing to action potential generation in DRG neurons and resultant conduction
blockade [158]; these results highlight the complex interactions underlying electrogenesis in
DRG neurons [159] and serve as a cautionary example against assuming a one-to-one
correlation between channel function and cellular excitability.
If DRG hyperexcitability due to enhanced NaV function is the root cause of select neuropathic
pain states, then it stands to reason that selective NaV antagonists should be antihyperalgesic.
Both synthetic [160164] and naturally occurring [165167] small molecule inhibitors of NaV1.7
have shown promise as antihyperalgesics in animal studies, as has a NaV1.7-specic monoclonal antibody [165]. Despite clearly identied limitations in the preclinical data [168,169], a
number of early stage (Phase I/II) human studies testing NaV1.7 and NaV1.8 blockers as


Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21


rNav1.1 (SCN1A)
rNav1.2 (SCN2A)
rNav1.3 (SCN3A)
rNav1.7 (SCN9A)
rNav1.4 (SCN4A)
rNav1.6 (SCN8A)
rNav1.5 (SCN5A)
rNav1.8 (SCN10A)
rNav1.9 (SCN11A)





Amino acid sequence dierences (%)


Conducon pore module


Voltage sensor module

+H N




+H N




S4-S5 linker

Figure 4. NaV Family Tree and Structural Architecture. (A) Amino acid sequence similarity of rat (r)NaV1.1NaV1.9 / subunits. Gene names are shown to the right of
the protein name. (B) A transmembrane folding diagram of the NaV1.2 channel. Cylinders represent /-helical segments. Bold lines represent the polypeptide chains of
each subunit, with a length approximately proportional to the number of amino acid residues in the brain sodium channel subtypes. The extracellular domains of the b1
and b2 subunits are shown as immunoglobulin-like folds. C, Sites of probable N-linked glycosylation; P in red, sites of demonstrated protein phosphorylation by protein
kinase A (circles) and protein kinase C (diamonds); blue, pore-lining segments; yellow circles, the outer (EEEE) and inner (DEKA) rings of amino residues that form the
tetrodotoxin-binding site and ion selectivity lter; green, S1S4 voltage sensors; h in blue circle, inactivation particle in the inactivation gate loop; blue circles, sites
implicated in forming the inactivation gate receptor. (C) Intramembrane view (left panel) of structural model of NaV1.7 channel transmembrane domains. Domain I, light
blue; Domain II, salmon; Domain III, cyan; Domain IV, lime. Cytosolic view (right panel) of the structural model of NaV1.7 channel transmembrane domains. (D) Side view of
NaVAb channels: voltage-sensing module (green); pore module (purple); S4S5 linker (red). (A and legend) Modied, with permission, from [138]. (B, D, and legend)
Modied, with permission, from [240]. (C and legend) Modied, with permission, from [241].

antihyperalgesics can be identied in publically accessible clinical research databases (Table 2;

In a Phase II randomized, double-blind, placebo controlled study of 81 subjects with pain
associated with lumbosacral radiculopathy (identier NCT01561027), the NaV1.7 blocker
CNV1014802 was reported in a company (Convergence Pharmaceuticals) press release to
improve Pain IntensityNumerical Rating Scale scores by a small (0.43), but statistically
signicant (P = 0.0265), amount,iii but no other details were provided. A small single-center
study examined the safety, efcacy, tolerability, and pharmacokinetics of topically applied XPF002 (XEN402 8% w/w ointment) in subjects with primary/inherited erythromelalgia (identier
NCT01486446); the small (n = 8; n = 7 in XPF-002 group and n = 1 in placebo group) and
parallel (as opposed to crossover) group study design preclude drawing any denitive conclusions from the posted data on the website. A second study using topically
applied XPF-002 in subjects with postherpetic neuralgia has also been completed (identier
NCT01195636); data posted at indicate that no effect of study drug as
compared with placebo was observed for the primary endpoint (change in mean daily pain

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy


Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy






Clinical Trial Identiera[6_TD$IF]






UV-C light-induced


No results posted





Trigeminal neuralgia




No results posted
See text

4-[2-(3-Amino-1H-pyrazol4-yl)-4-chlorophenoxy]-5chloro-2-uoro-N-4thiazolylbenzenesulfonamide 4methylbenzenesulfonate


Diabetic peripheral
Inherited erythromelalgia


(7S)-10 -[[5-(Triuoromethyl)
benzodioxole-7,30 -indole]20 -one


Inherited erythromelalgia
Postherpetic neuralgia





Healthy volunteers with

capsaicin or UV-B lightsensitized skin


No results posted





Healthy volunteers with UV

light-sensitized skin


No results posted




Xenon and Teva



NCT indicates trials registered at; ISRCT indicates trial registered at
As of 16 March, 2016.


No results posted
No results posted

see text
See text

TIPS 1334 No. of Pages 21

Table 2. Phase I/II Human Clinical Trials with NaV1.7 or NaV1.8 Channel Blockers

TIPS 1334 No. of Pages 21

score from baseline to week 3, respectively, 0.94 (1.30 to0.58), n = 56, and[14_TD$IF] 0.97 (1.33
to0.61), n = 56). Data for orally administered XEN402 (identier NCT01090622) have been
reported in the peer-reviewed literature; this was from a single-center, multiple-dose, in-patient,
randomized, double-blind, placebo-controlled, crossover trial in subjects (n = 4) with inherited
erythromelalgia, and the authors reported that XEN402 (i) signicantly reduced the ability to
induce pain by heat or exercise, (ii) increased the time to maximal pain induction, and (iii)
signicantly reduced the amount of pain after induction [172]. While by no means conclusive,
those results plausibly demonstrate efcacy and in vivo target engagement in humans, the sine
qua non for proof-of-principle with regard to contemporary drug development.
NaV1.8, too, has received signicant attention with regard to drug development [173]. As with
NaV1.7, both synthetic [174181] and naturally occurring [182184] small molecule NaV1.8selective inhibitors have been described, which possess antihyperalgesic activity in preclinical
models of neuropathic pain. Of those, PF-01247324 [6-amino-N-methyl-5-(2,3,5-trichlorophenyl)pyridine-2-carboxamide] appears particularly promising. PF-01247324 inhibits both
heterologously expressed human NaV1.8 channels and tetrodotoxin-resistant NaV currents
in rat DRG neurons in a state- and frequency-dependent manner, reduces excitability of both
rat and human DRG neurons in vitro, has high (F = 91%) oral bioavailability, and produces
antinociceptive effects in inammatory and peripheral nerve injury neuropathic pain models
Human trials have been initiated to study the efcacy of NaV1.8 inhibitors as antihyperalgesics,
one with DSP-2230 ([2_TD$IF]Sumitomo[15_TD$IF] Dainippon Pharma, Osaka, Japan) and the other with PF04531083 (Pzer, New York, NY, USA) [170,171]. DSP-2230 has been studied in human control
subjects using capsaicin- and UV-B light-induced cutaneous sensitization but no results have
been reported (identier ISRCTN80154838). Similarly, the study on the effect of PF-04531083
on heat pain in healthy volunteers, also with UV light-sensitized skin, has been completed
(identier NCT01127906) and again no results reported. The structural similarity between PF01247324 and PF-04531083 (both are substituted carboxamide derivatives) suggests that PF04531083 may yet prove to be effective, but one can reasonably infer that the NCT01127906
study results were less than impressive given that the study was closed to subject accrual in
2010 and no further information provided. Additional clinical trials with NaV1.8 blockers are
necessary to determine the efcacy of such antagonism in patients with neuropathic pain
associated with NaV1.8 gain-of-function mutations; if safety and efcacy can be demonstrated
in this patient population, it might then be reasonable to determine whether such agents have
broader indications for use.
As noted earlier, NaV1.9 gain-of-function mutations have been identied in patients with small
ber neuropathy [156] and familial episodic pain [157], and a compelling argument has been
made for NaV1.9 as validated human therapeutic target [142]. No highly selective blocker of
NaV1.9 has been identied thus far [184], and the search for suitable candidates has been
hampered by exceedingly poor heterologous expression in host cells. Using a NaV1.4/1.9
chimeric approach, it has been shown that limited NaV1.9 expression results arise from the
C-terminal structure of the protein [185]. Use of chimeras that preserve the entire NaV1.9
transmembrane domain offers hope for development of inhibitors, although only those that do
not act on the intracellular motifs of the isoform.
Is a drug that is selective for a wild-type channel isoform an a priori condition for clinical efcacy?
The answer is maybe not. Mexiletine [1-methyl-2-(2,6-xylyloxy)ethylamine hydrochloride] is a
Class 1b antiarrhythmic that is structurally related to lidocaine; it blocks multiple NaV-type
channels, including NaV1.2 [186], NaV1.4 [187], NaV1.5 [188], NaV1.7 [189], as well as tetrodotoxin-resistant Na+[13_TD$IF] currents (presumably mediated by NaV1.8 and/or NaV1.9; [138]) in DRG

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy


TIPS 1334 No. of Pages 21

neurons [186]. Early reports suggested that orally administered mexiletine could possibly
improve neuropathic pain associated with idiopathic sensorimotor polyneuropathy, chemotherapy administration, diabetes [190,191], and erythromelalgia [192,193]. Subsequent reports also
suggested that oral mexiletine could improve pain symptoms in some, but perhaps not all,
patients with NaV1.7-linked erythromelalgia [189,194,195]. A patient with the NaVI848 T variant
reported mild improvement in their pain when treated with acetaminophen plus mexiletine,
whereas a patient with the NaVV1316A variant reported little or no relief with a poly drug regimen
that included mexiletine [189]. Notably, the mexiletine IC50 for NaV1.7I848 T channel currents (at
steady state) is 1.08 mM, whereas the IC50 for wild-type NaV1.7, NaV1.7I136 V, and NaVV1316A
channels is 1.77, 2.03, and 1.73 mM, respectively [189]. Another mutation (Nav1.7V872G) is
also linked to mexiletine-responsive erythromelalgia; this channel has a mexiletine IC50 that is
similar to that of the wild-type channel, but shows more pronounced use-dependent block [194].
More recently, it has been shown that mexiletine impairs NaV1.7 channel gating and decreases
window currents in mutant NaV1.7L58F channels to a greater degree than wild-type channels
[196]; while the NaV1.7L58F mutation is linked to erythromelalgia [197,198], it is unknown
whether mexiletine is clinically effective in that patient population, but the in vitro data suggest
that it may be efcacious. For disorders such as erythromelalgia that exhibit genetic heterogeneity, appropriate genetic screening of patients may be required when considering whether an
NCE has clinical utility or not.

Concluding Remarks
It is evident that the data from preclinical animal models offers, in many instances, compelling
arguments for a particular molecular pathway as being of fundamental importance to the
development, maintenance, and therapeutic target value in neuropathic pain. Based on those
results, human clinical trials are designed, subjects enrolled, data collated and subjected to
multivariate analysis, and report, all too frequently, no signicant effect [199]; the results with the
CaV3.2 blocker ABT-639 are a case in point. This apparent disconnect between the animal and
human data has led to repeated calls for a fundamental rethinking of how we approach the
problem of developing new analgesics for the treatment of neuropathic pain [48,199,200].
Many, but by no means all, of the basic molecular and cellular aspects of acute nociception
appear to be conserved across species [199]. But mice are far from human, however, and pain is
not merely an unpleasant sensory experience, but includes an emotional/affective component
that the most commonly used tests for nociception (mechanical and thermal testing with von
Frey laments and a Hargreaves apparatus, respectively) cannot gauge. In the same vein, relying
on constitutive gene deletion (global or spatially restricted) animal models to conrm whether the
putative target protein is necessary and sufcient for the development and maintenance of
neuropathic pain can lead to false conclusions as to the relative contribution of the protein in
question to the pathological state [201]; exemplifying this point is the observation that neither
NaV1.7 nor NaV1.8, alone or in combination, appears to be required for the development of
neuropathic pain [202], yet selective NaV antagonists are antihyperalgesic in neuropathic pain
models. Similarly, Hcn1 or Hcn2 gene deletion minimizes or abolishes different aspects of
neuropathic pain [95,203,204] with HCN1 clearly contributing to cold allodynia [95,203]. While
many other aspects of neuropathic pain are preserved despite HCN1 deletion, the role of HCN1
in pathological-mediated neuropathic pain may not be equivalent to measuring the initiation/
development of such pain when it is constitutively absent; thus, HCN1 expression is upregulated
in response to nerve injury [109], diabetes [118], and exposure to chemotherapeutics [119,120].
To examine this further, the efcacy of ivabradine and alkylphenol inhibitors of HCN1 need to be
examined in the absence of HCN1.
So perhaps we are designing the wrong paradigms and measuring the wrong outcome(s) in the
current preclinical studies and what we are seeing are in effect false positives. Alternative tests


Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

Outstanding Questions
What are the molecular targets in
peripheral sensory neurons that are
most relevant to the development
and maintenance of neuropathic pain?
Do the same molecular targets contribute equally to neuropathic pain regardless of the inciting event?
Is the current approach to identifying
putative targets in animals correct, or
should we rst be identifying the targets
in humans with neuropathic pain and
then establishing the mechanisms/
pathways in animals for validation (i.
e., going from bedside to bench
rather than bench to bedside)?
Are the current widely used approaches
to measuring pain in animals[16_TD$IF] [17_TD$IF] mechanical threshold testing with von Frey laments and thermal sensitivity testing
using the Hargreaves method[18_TD$IF] [19_TD$IF] sufcient when assessing neuropathic pain
or should additional testing modalities
be routinely incorporated?
Are the validated survey tools for
assessing human pain in general, and
neuropathic pain in particular, sufcient
to detect antihyperalgesic efcacy when
evaluating NCEs? Can we establish new
biomarkers, be they molecular, composite using multiple measures, or
image (fMRI or PET scan) generated,
that can be used to conrm in vivo target
engagement? How would we reconcile
discrepant results between biomarker
studies and self-report of effect?
In the past, highly selective therapeutics has been the gold standard with
regard to drug development. In the
event that multiple targets contribute
in some combination to a given type
of neuropathic pain (i.e., diabetic painful neuropathy, where both CaV3 and
HCN channels appear to play a contributory role), is a highly selective drug
in fact desirable? Would a combination medication that has active ingredients that target each pathologic
component separately be the more
logical approach? What about a single
drug but one that was less selective?

TIPS 1334 No. of Pages 21

that may offer a better assessment of complex animal behavior, and which may capture the full
neuropathic experience, include place conditioning and avoidance [205207], analgesic selfadministration [208,209], pain-induced rodent facial expression [210,211] (similar to the scale
used to assess pain in human premature neonates [212]), motor activity (wheel running
[213,214] and burrowing [215,216]), and vocalization [217,218]. Identication of a putative
molecular target, and corresponding novel selective therapeutic agent, will likely require testing
using multiple preclinical models to provide a cumulative predictive measure of both the target
and the ligand. As with human clinical trials, there is a need for consistent, uniform reporting of
preclinical in vivo methodologies as well as clearly dened a priori approaches to data analysis
and interpretation, particularly with regard to estimates of number needed to treat (NNT) and
clinical effect size [219].
To paraphrase Shakespeare, the fault, perhaps, is not in our models, but in ourselves. Neuropathic pain can result from both de novo and inherited mutations and, as such, genome wide
association studies (GWASs) may aid in the identication of specic mutations that contribute to
neuropathic pain, such as those associated with inherited erythromelalgia. Identifying relevant
molecular targets using GWAS approaches will likely provide the most meaningful results where
a single, or few, gene(s) is/are involved. These results can then be used to construct appropriate
animal studies in which novel therapeutics can be tested prior to initiating Phase I human studies.
In studies that rely on subjective reports of improvement, placebo effects are frequently high in
human trials of analgesics for the treatment of neuropathic pain, making it difcult to discern true
clinical benet of the active comparator [220]. As recommended by The Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group, better design and
improved reporting of numerous parameters (including those broadly pertaining to patient
factors, study design, study site, and outcome measures), will enhance the sensitivity of
randomized clinical trials [221]. By way of example, this would include the use of a crossover
study design as it may require a smaller sample size than a parallel-designed study and may have
increased assay sensitivity; other recommendations based on retrospective quantitative analysis
of randomized controlled trials (RCTs) or relevant observational studies were that study duration
be at least 12 weeks and that subjects receive appropriate training as personal expectations
(i.e., bias) can inuence reporting of active treatment and placebo group improvement. Had the
ABT-639 study [51] followed the IMMPACT guidelines, it is possible the authors might have
reached a very different conclusion. Finally, the identication of validated, molecular, biomarkers
for neuropathic pain will facilitate the testing of potential therapeutics in both the preclinical and
clinical setting; unfortunately, such markers do net yet exist although the use of miRNAs holds
promise [222]. In vivo imaging [as with positron emission tomography (PET) and/or fMRI] is an
alternative biomarker methodology [223], which may be able to identify pain phenotypes [224]
and guide analgesic drug development [225,226]. Such imaging biomarkers may also identify
supraspinal circuits that contribute to the cognitive/affective components of neuropathic pain,
which may provide alternative therapeutic targets to those present in sensory neurons [59,227].
So many targets, so many potential novel analgesics. In many instances, data from animal
model studies provide compelling arguments supporting the role of select CaV, HCN, and
NaV channels in neuropathic pain arising from a variety of pathophysiological states. For NaV
channels, human correlates exist conrming the role of these channels in peripheral neuropathic pain and, at present, offer an excellent opportunity for NCE development for specic
neuropathic conditions. CaV2.2 channels also present an exciting avenue for additional
drug development, but eliminating CNS toxicity (as seen with ziconotide) will be crucial in
determining the translational potential of such compounds. Finally, CaV3.2 and HCN (HCN1
in particular) channels present wide open opportunities with regard to drug development;
whether they contribute to a specic neuropathic condition (as seen with NaV1.7 and
erythromelalgia, for example) or are more generally involved in hyperexcitability and/or

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy


TIPS 1334 No. of Pages 21

spontaneous activity in human primary afferent neurons is unknown. Ultimately, which NCEs,
if any, will transition from bench to bedside remains to be seen; numerous questions must be
addressed to successfully bridge the gap between the apparent promise of preclinical data
and the paucity of such promise in human trials (see Outstanding Questions). And the search
goes on.




International Association for the Study of Pain, Subcommittee on

Taxonomy (1986) Classication of chronic pain. Descriptions of
chronic pain syndromes and denitions of pain terms. Pain
Suppl. 3, S1S226


Gaskin, D.J. and Richard, P. (2012) The economic costs of pain

in the United States. J. Pain 13, 715724

21. Nowycky, M.C. et al. (1985) Three types of neuronal calcium

channel with different calcium agonist sensitivity. Nature 316,


Meier, B. and Marsh, B. (2013) The soaring cost of the opioid

economy. In The New York Times. The New York Times

22. Bossu, J.L. et al. (1985) Depolarization elicits two distinct calcium
currents in vertebrate sensory neurones. Pgers Arch. 403,


Paulozzi, L.J. et al. (2011) Vital signs: overdoses of prescription

opioid pain relievers United States, 19992008. Morb. Mortal.
Wly Rep. 60, 14871492

23. Fedulova, S.A. et al. (1985) Two types of calcium channels in the
somatic membrane of new-born rat dorsal root ganglion neurones. J. Physiol. 359, 431446


Centers for Disease Control and Prevention (2015) National Vital

Statistics System Mortality Data, Centers for Disease Control and

24. Talley, E.M. et al. (1999) Differential distribution of three members

of a gene family encoding low voltage-activated (T-type) calcium
channels. J. Neurosci. 19, 18951911


Lyapustina, T. and Alexander, G.C. (2015) The prescription

opioid addiction and abuse epidemic: how it happened and what
we can do about it. Pharm. J. June, 294

25. Shin, J.B. et al. (2003) A T-type calcium channel required for
normal function of a mammalian mechanoreceptor. Nat. Neurosci. 6, 724730


Degenhardt, L. et al. (2014) The global epidemiology and burden

of opioid dependence: results from the global burden of disease
2010 study. Addiction 109, 13201333


Campbell, G. et al. (2015) Pharmaceutical opioid use and dependence among people living with chronic pain: associations
observed within the Pain and Opioids in Treatment (POINT)
cohort. Pain Med. 16, 17451758

26. Rose, K.E. et al. (2013) Immunohistological demonstration of

CaV3.2 T-type voltage-gated calcium channel expression in
soma of dorsal root ganglion neurons and peripheral axons of
rat and mouse. Neuroscience 250, 263274


Bohnert, A.S. et al. (2011) Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305,

10. Giraudon, I. et al. (2013) Prescription opioid abuse in the UK. Br.
J. Clin. Pharmacol. 76, 823824
11. Gaskell, H. et al. (2014) Oxycodone for neuropathic pain and
bromyalgia in adults. Cochrane Database Syst. Rev. 6,

20. Carbone, E. and Lux, H.D. (1984) A low voltage-activated, fully

inactivating Ca channel in vertebrate sensory neurones. Nature
310, 501502

27. Jagodic, M.M. et al. (2007) Cell-specic alterations of T-type

calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J. Neurosci. 27, 33053316
28. Nelson, M.T. et al. (2005) The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a
novel subpopulation of rat peripheral nociceptors. J. Neurosci.
25, 87668775
29. Franois, A. et al. (2014) T-type calcium channels in chronic
pain: mouse models and specic blockers. Pgers Arch. 466,

12. Wiffen, P.J. et al. (2015) Buprenorphine for neuropathic pain in

adults. Cochrane Database Syst. Rev. 9, CD011603

30. Lacinov, L. (2004) Pharmacology of recombinant low-voltage

activated calcium channels. Curr. Drug Targets CNS Neurol.
Disord. 3, 105111

13. Freynhagen, R. and Bennett, M.I. (2009) Diagnosis and management of neuropathic pain. BMJ 339, b3002

31. Todorovic, S.M. et al. (2001) Redox modulation of T-type calcium

channels in rat peripheral nociceptors. Neuron 31, 7585

14. von Hehn, C.A. et al. (2012) Deconstructing the neuropathic

pain phenotype to reveal neural mechanisms. Neuron 73,

32. Bourinet, E. et al. (2005) Silencing of the Cav3.2 T-type calcium

channel gene in sensory neurons demonstrates its major role in
nociception. EMBO J. 24, 315324

15. Costigan, M. et al. (2009) Neuropathic pain: a maladaptive

response of the nervous system to damage. Annu. Rev. Neurosci. 32, 132

33. Jagodic, M.M. et al. (2008) Upregulation of the T-type calcium

current in small rat sensory neurons after chronic constrictive
injury of the sciatic nerve. J. Neurophysiol. 99, 31513156

16. Scholz, J. and Woolf, C.J. (2007) The neuropathic pain triad:
neurons, immune cells and glia. Nat. Neurosci. 10, 13611368

34. Watanabe, M. et al. (2015) Expression and regulation of Cav3.2

T-type calcium channels during inammatory hyperalgesia in
mouse dorsal root ganglion neurons. PLoS ONE 10, e0127572

17. West, S.J. et al. (2015) Circuitry and plasticity of the dorsal horn
toward a better understanding of neuropathic pain. Neuroscience 300, 254275
18. Catterall, W.A. et al. (2005) International Union of Pharmacology. XLVIII. Nomenclature and structurefunction relationships of voltage-gated calcium channels. Pharmacol. Rev.
57, 411425
19. Furukawa, T. (2013) Types of voltage-gated calcium channels:
molecular and electrophysiological views. Curr. Hypertens. Rev.
9, 170181


35. Yue, J. et al. (2013) Upregulation of T-type Ca2+ channels in

primary sensory neurons in spinal nerve injury. Spine (Phila Pa
1976) 38, 463470
36. Dogrul, A. et al. (2003) Reversal of experimental neuropathic pain
by T-type calcium channel blockers. Pain 105, 159168
37. Todorovic, S.M. and Jevtovic-Todorovic, V. (2014) Targeting of
CaV3.2 T-type calcium channels in peripheral sensory neurons for
the treatment of painful diabetic neuropathy. Pgers Arch. 466,

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

38. Yusaf, S.P. et al. (2001) Streptozocin-induced neuropathy is

associated with altered expression of voltage-gated calcium
channel subunit mRNAs in rat dorsal root ganglion neurones.
Biochem. Biophys. Res. Commun. 289, 402406
39. Cao, X.H. et al. (2011) Diabetic neuropathy enhances voltageactivated Ca2+ channel activity and its control by M4 muscarinic
receptors in primary sensory neurons. J. Neurochem. 119, 594
40. Khomula, E.V. et al. (2013) Specic functioning of Cav3.2 T-type
calcium and TRPV1 channels under different types of STZ-diabetic neuropathy. Biochim. Biophys. Acta 1832, 636649
41. Messinger, R.B. et al. (2009) In vivo silencing of the CaV3.2 T-type
calcium channels in sensory neurons alleviates hyperalgesia in
rats with streptozocin-induced diabetic neuropathy. Pain 145,
42. Coleman, D.L. (1982) Diabetes-obesity syndromes in mice. Diabetes 31, 16
43. Drel, V.R. et al. (2006) The leptin-decient (ob/ob) mouse: a new
animal model of peripheral neuropathy of type 2 diabetes and
obesity. Diabetes 55, 33353343
44. Latham, J.R. et al. (2009) Selective T-type calcium channel
blockade alleviates hyperalgesia in ob/ob mice. Diabetes 58,
45. Todorovic, S.M. et al. (1998) Enantioselective blockade of
T-type Ca2+ current in adult rat sensory neurons by a steroid
that lacks g-aminobutyric acid-modulatory activity. Mol. Pharmacol. 54, 918927

60. Duff, E.P. et al. (2015) Learning to identify CNS drug action and
efcacy using multistudy fMRI data. Sci. Transl. Med. 7,
61. Wartolowska, K. and Tracey, I. (2009) Neuroimaging as a tool for
pain diagnosis and analgesic development. Neurotherapeutics 6,
62. Wanigasekera, V. et al. (2016) Disambiguating pharmacodynamic efcacy from behavior with neuroimaging: implications
for analgesic drug development. Anesthesiology 124, 159168
63. Yusaf, S.P. et al. (2001) Expression of voltage-gated calcium
channel subunits in rat dorsal root ganglion neurons. Neurosci.
Lett. 311, 137141
64. Scroggs, R.S. and Fox, A.P. (1992) Calcium current variation
between acutely isolated adult rat dorsal root ganglion neurons of
different size. J. Physiol. 445, 639658
65. Scroggs, R.S. and Fox, A.P. (1992) Multiple Ca2+ currents elicited by action potential waveforms in acutely isolated adult rat
dorsal root ganglion neurons. J. Neurosci. 12, 17891801
66. Yu, C. et al. (1992) Heterogeneous calcium currents and transmitter release in cultured mouse spinal cord and dorsal root
ganglion neurons. J. Neurophysiol. 67, 561575
67. Ellinor, P.T. et al. (1994) Structural determinants of the blockade
of N-type calcium channels by a peptide neurotoxin. Nature 372,
68. Feng, Z.P. et al. (2001) Residue Gly1326 of the N-type calcium
channel a1B subunit controls reversibility of -conotoxin GVIA
and MVIIA block. J. Biol. Chem. 276, 1572815735

46. Orestes, P. et al. (2013) Reversal of neuropathic pain in diabetes

by targeting glycosylation of CaV3.2 T-type calcium channels.
Diabetes 62, 38283838

69. Liang, H. and Elmslie, K.S. (2002) Rapid and reversible block
of N-type calcium channels (CaV 2.2) by -conotoxin GVIA
in the absence of divalent cations. J. Neurosci. 22, 88848890

47. Garca-Caballero, A. et al. (2014) The deubiquitinating enzyme

USP5 modulates neuropathic and inammatory pain by enhancing Cav3.2 channel activity. Neuron 83, 11441158

70. Heinke, B. et al. (2004) Pre- and postsynaptic contributions

of voltage-dependent Ca2+ channels to nociceptive transmission in rat spinal lamina I neurons. Eur. J. Neurosci. 19,

48. Mao, J. (2012) Current challenges in translational pain research.

Trends Pharmacol. Sci. 33, 568573
49. Jarvis, M.F. et al. (2014) A peripherally acting, selective T-type
calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem. Pharmacol. 89,
50. Serra, J. et al. (2015) Effects of a T-type calcium channel blocker,
ABT-639, on spontaneous activity in C-nociceptors in patients
with painful diabetic neuropathy: a randomized controlled trial.
Pain 156, 21752183
51. Ziegler, D. et al. (2015) A randomized double-blind, placebo-,
and active-controlled study of T-type calcium channel blocker
ABT-639 in patients with diabetic peripheral neuropathic pain.
Pain 156, 20132020
52. Lee, M. (2014) Z944: a rst in class T-type calcium channel
modulator for the treatment of pain. J. Periph. Nerv. Sys. 19
(Suppl. 2), S11S12
53. Tringham, E. et al. (2012) T-type calcium channel blockers that
attenuate thalamic burst ring and suppress absence seizures.
Sci. Transl. Med. 4, 121ra119
54. An, G. et al. (2015) Erratum to: population pharmacokinetics and
exposure-uric acid analyses after single and multiple doses of
ABT-639, a calcium channel blocker, in healthy volunteers. AAPS
J. 17, 481492
55. Baliki, M.N. et al. (2014) Functional reorganization of the default
mode network across chronic pain conditions. PLoS ONE 9,
56. Kucyi, A. et al. (2014) Enhanced medial prefrontal-default mode
network functional connectivity in chronic pain and its association
with pain rumination. J. Neurosci. 34, 39693975
57. Hemington, K.S. et al. (2015) Abnormal cross-network functional
connectivity in chronic pain and its association with clinical
symptoms. Brain Struct. Funct. Published online December
15, 2015.
58. Apkarian, A.V. et al. (2011) Pain and the brain: specicity and
plasticity of the brain in clinical chronic pain. Pain 152, S49S64
59. Bingel, U. et al. (2011) The effect of treatment expectation on
drug efcacy: imaging the analgesic benet of the opioid remifentanil. Sci. Transl. Med. 3, 70ra14

71. Matthews, E.A. and Dickenson, A.H. (2001) Effects of spinally

delivered N- and P-type voltage-dependent calcium channel
antagonists on dorsal horn neuronal responses in a rat model
of neuropathy. Pain 92, 235246
72. Chaplan, S.R. et al. (1994) Role of voltage-dependent calcium
channel subtypes in experimental tactile allodynia. J. Pharmacol.
Exp. Ther. 269, 11171123
73. Lynch, S.S. et al. (2006) Intrathecal ziconotide for refractory
chronic pain. Ann. Pharmacother. 40, 12931300
74. Ogiyama, T. et al. (2015) Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium
channel blocker for neuropathic pain. Bioorg. Med. Chem. 23,
75. Ogiyama, T. et al. (2015) Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel
blocker for neuropathic pain without CYP inhibition liability. Bioorg. Med. Chem. 23, 46384648
76. Mollica, A. et al. (2015) Design, synthesis and biological evaluation of two opioid agonist and Cav2.2 blocker multitarget ligands.
Chem. Biol. Drug Des. 86, 156162
77. Biel, M. et al. (2009) Hyperpolarization-activated cation channels:
from genes to function. Physiol. Rev. 89, 847885
78. Wahl-Schott, C. and Biel, M. (2009) HCN channels: structure,
cellular regulation and physiological function. Cell. Mol. Life Sci.
66, 470494
79. Santoro, B. et al. (1998) Identication of a gene encoding a
hyperpolarization-activated pacemaker channel of brain. Cell
93, 717729
80. Ludwig, A. et al. (1998) A family of hyperpolarization-activated
mammalian cation channels. Nature 393, 587591
81. Ludwig, A. et al. (1999) Two pacemaker channels from human
heart with profoundly different activation kinetics. EMBO J. 18,
82. Seifert, R. et al. (1999) Molecular characterization of a slowly
gating human hyperpolarization-activated channel predominantly expressed in thalamus, heart, and testis. Proc. Natl. Acad.
Sci. U.S.A. 96, 93919396

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy


TIPS 1334 No. of Pages 21

83. Ishii, T.M. et al. (1999) Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial
node. J. Biol. Chem. 274, 1283512839
84. Whitaker, G.M. et al. (2007) HCN2 and HCN4 isoforms selfassemble and co-assemble with equal preference to form functional pacemaker channels. J. Biol. Chem. 282, 2290022909
85. Much, B. et al. (2003) Role of subunit heteromerization and Nlinked glycosylation in the formation of functional hyperpolarization-activated cyclic nucleotide-gated channels. J. Biol. Chem.
278, 4378143786
86. Chen, S. et al. (2001) Properties of hyperpolarization-activated
pacemaker current dened by coassembly of HCN1 and HCN2
subunits and basal modulation by cyclic nucleotide. J. Gen.
Physiol. 117, 491504
87. Altomare, C. et al. (2003) Heteromeric HCN1HCN4 channels: a
comparison with native pacemaker channels from the rabbit
sinoatrial node. J. Physiol. 549, 347359
88. Zhang, Q. et al. (2009) Associated changes in HCN2 and HCN4
transcripts and If pacemaker current in myocytes. Biochim.
Biophys. Acta 1788, 11381147
89. Brown, H.F. et al. (1979) How does adrenaline accelerate the
heart? Nature 280, 235236
90. Robinson, R.B. and Siegelbaum, S.A. (2003) Hyperpolarizationactivated cation currents: from molecules to physiological function. Annu. Rev. Physiol. 65, 453480
91. He, C. et al. (2014) Neurophysiology of HCN channels: from
cellular functions to multiple regulations. Prog. Neurobiol. 112,
92. Moosmang, S. et al. (1999) Differential distribution of four hyperpolarization-activated cation channels in mouse brain. Biol.
Chem. 380, 975980
93. Notomi, T. and Shigemoto, R. (2004) Immunohistochemical
localization of Ih channel subunits, HCN1-4, in the rat brain. J.
Comp. Neurol. 471, 241276
94. Kouranova, E.V. et al. (2008) Hyperpolarization-activated cyclic
nucleotide-gated channel mRNA and protein expression in large
versus small diameter dorsal root ganglion neurons: correlation
with hyperpolarization-activated current gating. Neuroscience
153, 10081019
95. Momin, A. et al. (2008) Role of the hyperpolarization-activated
current Ih in somatosensory neurons. J. Physiol. 586, 59115929
96. Gao, L.L. et al. (2012) Expression and properties of hyperpolarization-activated current in rat dorsal root ganglion neurons with
known sensory function. J. Physiol. 590, 46914705

dorsal root ganglion neurons in a rat model of neuropathic pain.

Brain Res. 1032, 6369
108. Chaplan, S.R. et al. (2003) Neuronal hyperpolarization-activated
pacemaker channels drive neuropathic pain. J. Neurosci. 23,
109. Jiang, Y.Q. et al. (2008) Axonal accumulation of hyperpolarization-activated cyclic nucleotide-gated cation channels contributes to mechanical allodynia after peripheral nerve injury in rat.
Pain 137, 495506
110. Wells, J.E. et al. (2007) Hyperpolarization-activated channels in
trigeminal ganglia innervating healthy and pulp-exposed teeth.
Int. Endod. J. 40, 715721
111. Yao, H. et al. (2003) Upregulation of the hyperpolarization-activated cation current after chronic compression of the dorsal root
ganglion. J. Neurosci. 23, 20692074
112. Kitagawa, J. et al. (2006) Mechanisms involved in modulation of
trigeminal primary afferent activity in rats with peripheral mononeuropathy. Eur. J. Neurosci. 24, 19761986
113. Tsuboi, Y. et al. (2004) Alteration of the second branch of the
trigeminal nerve activity following inferior alveolar nerve transection in rats. Pain 111, 323334
114. Liu, C.N. et al. (2002) Subthreshold oscillations induced by spinal
nerve injury in dissociated muscle and cutaneous afferents of
mouse DRG. J. Neurophysiol. 87, 20092017
115. Lee, D.H. et al. (2005) Hyperpolarization-activated, cation-nonselective, cyclic nucleotide-modulated channel blockade alleviates mechanical allodynia and suppresses ectopic discharge in
spinal nerve ligated rats. J. Pain 6, 417424
116. Luo, L. et al. (2007) Role of peripheral hyperpolarization-activated
cyclic nucleotide-modulated channel pacemaker channels in
acute and chronic pain models in the rat. Neuroscience 144,
117. Dalle, C. and Eisenach, J.C. (2005) Peripheral block of the
hyperpolarization-activated cation current (Ih) reduces mechanical allodynia in animal models of postoperative and neuropathic
pain. Reg. Anesth. Pain Med. 30, 243248
118. Tu, H. et al. (2010) Diabetes alters protein expression of hyperpolarization-activated cyclic nucleotide-gated channel subunits
in rat nodose ganglion cells. Neuroscience 165, 3952
119. Descoeur, J. et al. (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol. Med. 3, 266278

97. Stillitano, F. et al. (2008) Molecular basis of funny current (If) in

normal and failing human heart. J. Mol. Cell. Cardiol. 45, 289299

120. Zhang, H. and Dougherty, P.M. (2014) Enhanced excitability of

primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced
peripheral neuropathy. Anesthesiology 120, 14631475

98. Thollon, C. et al. (2007) Use-dependent inhibition of hHCN4 by

ivabradine and relationship with reduction in pacemaker activity.
Br. J. Pharmacol. 150, 3746

121. Avan, A. et al. (2015) Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 20,

99. Chandler, N.J. et al. (2009) Molecular architecture of the human

sinus node: insights into the function of the cardiac pacemaker.
Circulation 119, 15621575

122. Boyette-Davis, J.A. et al. (2015) Mechanisms involved in the

development of chemotherapy-induced neuropathy. Pain
Manag. 5, 285296

100. Li, N. et al. (2015) Molecular mapping of sinoatrial node HCN

channel expression in the human heart. Circ. Arrhythm. Electrophysiol. 8, 12191227

123. Bucchi, A. et al. (2006) Properties of ivabradine-induced block of

HCN1 and HCN4 pacemaker channels. J. Physiol. 572, 335346

101. Postea, O. and Biel, M. (2011) Exploring HCN channels as novel

drug targets. Nat. Rev. Drug Discov. 10, 903914
102. Wang, L.X. and Wang, Z.J. (2003) Animal and cellular models of
chronic pain. Adv. Drug Deliv. Rev. 55, 949965
103. Campbell, J.N. and Meyer, R.A. (2006) Mechanisms of neuropathic pain. Neuron 52, 7792
104. Song, X.J. et al. (1999) Mechanical and thermal hyperalgesia and
ectopic neuronal discharge after chronic compression of dorsal
root ganglia. J. Neurophysiol. 82, 33473358
105. Liu, C.N. et al. (2000) Tactile allodynia in the absence of C-ber
activation: altered ring properties of DRG neurons following
spinal nerve injury. Pain 85, 503521
106. Liu, C.N. et al. (2000) Spinal nerve injury enhances subthreshold
membrane potential oscillations in DRG neurons: relation to
neuropathic pain. J. Neurophysiol. 84, 205215
107. Sun, Q. et al. (2005) Inhibition of hyperpolarization-activated
current by ZD7288 suppresses ectopic discharges of injured


124. Stieber, J. et al. (2006) Bradycardic and proarrhythmic properties

of sinus node inhibitors. Mol. Pharmacol. 69, 13281337
125. Bois, P. et al. (1996) Mode of action of bradycardic agent,
S16257, on ionic currents of rabbit sinoatrial node cells. Br. J.
Pharmacol. 118, 10511057
126. Young, G.T. et al. (2014) Inammatory and neuropathic pain
are rapidly suppressed by peripheral block of hyperpolarisation-activated cyclic nucleotide-gated ion channels. Pain 155,
127. Jiang, J. et al. (2013) Development and validation of a sensitive
LC-MS/MS-ESI method for the determination of ivabradine in
human plasma: application to a pharmacokinetic study. Biomed.
Chromatogr. 27, 16031608
128. Vlase, L. et al. (2011) Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J. Clin. Pharm.
Ther. 36, 225229
129. Ragueneau, I. et al. (1998) Pharmacokineticpharmacodynamic
modeling of the effects of ivabradine, a direct sinus node inhibitor,

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

on heart rate in healthy volunteers. Clin. Pharmacol. Ther. 64,

130. Borer, J.S. et al. (2003) Antianginal and antiischemic effects of
ivabradine, an If inhibitor, in stable angina: a randomized, doubleblind, multicentered, placebo-controlled trial. Circulation 107,
131. Lopez-Bescos, L. et al. (2007) Long-term safety and efcacy of
ivabradine in patients with chronic stable angina. Cardiology 108,
132. Tibbs, G.R. et al. (2013) HCN1 channels as targets for anesthetic
and non-anesthetic propofol analogs in the amelioration of
mechanical and thermal hyperalgesia in a mouse model of neuropathic pain. J. Pharmacol. Exp. Ther. 345, 363373
133. Chen, X. et al. (2005) Suppression of Ih contributes to propofolinduced inhibition of mouse cortical pyramidal neurons. J. Neurophysiol. 94, 38723883
134. Bucchi, A. et al. (2007) Heart rate reduction via selective funny
channel blockers. Curr. Opin. Pharmacol. 7, 208213
135. Shin, K.S. et al. (2001) Blocker state dependence and trapping in
hyperpolarization-activated cation channels: evidence for an
intracellular activation gate. J. Gen. Physiol. 117, 91101
136. Cheng, L. et al. (2007) Molecular mapping of the binding site
for a blocker of hyperpolarization-activated, cyclic nucleotidemodulated pacemaker channels. J. Pharmacol. Exp. Ther. 322,

154. Han, C. et al. (2014) The G1662S NaV1.8 mutation in small bre
neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J. Neurol. Neurosurg. Psychiatry 85, 499505
155. Huang, J. et al. (2013) Small-ber neuropathy Nav1.8 mutation
shifts activation to hyperpolarized potentials and increases
excitability of dorsal root ganglion neurons. J. Neurosci. 33,
156. Huang, J. et al. (2014) Gain-of-function mutations in sodium
channel Nav1.9 in painful neuropathy. Brain 137, 16271642
157. Zhang, X.Y. et al. (2013) Gain-of-function mutations in SCN11A
cause familial episodic pain. Am. J. Hum. Genet. 93, 957966
158. Leipold, E. et al. (2013) A de novo gain-of-function mutation
in SCN11A causes loss of pain perception. Nat. Genet. 45,
159. Rush, A.M. et al. (2007) Multiple sodium channels and their roles
in electrogenesis within dorsal root ganglion neurons. J. Physiol.
579, 114
160. Macsari, I. et al. (2012) 3-Oxoisoindoline-1-carboxamides:
potent, state-dependent blockers of voltage-gated sodium
channel NaV1.7 with efcacy in rat pain models. J. Med. Chem.
55, 68666880
161. Williams, B.S. et al. (2007) Characterization of a new class of
potent inhibitors of the voltage-gated sodium channel Nav1.7.
Biochemistry 46, 1469314703

137. Stieber, J. et al. (2005) Functional expression of the human HCN3

channel. J. Biol. Chem. 280, 3463534643

162. London, C. et al. (2008) Imidazopyridines: a novel class of

hNav1.7 channel blockers. Bioorg. Med. Chem. Lett. 18,

138. Catterall, W.A. et al. (2005) International Union of Pharmacology.

XLVII. Nomenclature and structurefunction relationships of voltage-gated sodium channels. Pharmacol. Rev. 57, 397409

163. Bregman, H. et al. (2011) Identication of a potent, state-dependent inhibitor of Nav1.7 with oral efcacy in the formalin model of
persistent pain. J. Med. Chem. 54, 44274445

139. Waxman, S.G. et al. (2014) Sodium channel genes in pain-related

disorders: phenotypegenotype associations and recommendations for clinical use. Lancet Neurol. 13, 11521160

164. Chowdhury, S. et al. (2011) Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain. Bioorg. Med.
Chem. Lett. 21, 36763681

140. Hoeijmakers, J.G. et al. (2015) Painful peripheral neuropathy and

sodium channel mutations. Neurosci. Lett. 596, 5159

165. Lee, J.H. et al. (2014) A monoclonal antibody that targets a

NaV1.7 channel voltage sensor for pain and itch relief. Cell
157, 13931404

141. Habib, A.M. et al. (2015) Sodium channels and pain. Handb. Exp.
Pharmacol. 227, 3956
142. Dib-Hajj, S.D. et al. (2015) NaV1.9: a sodium channel linked to
human pain. Nat. Rev. Neurosci. 16, 511519
143. Hisama, F.M. et al. (1993) SCN9A-related inherited erythromelalgia. In GeneReviews (Pagon, R.A. et al., eds), University of
Washington, Seattle
144. Dib-Hajj, S.D. et al. (2005) Gain-of-function mutation in Nav1.7 in
familial erythromelalgia induces bursting of sensory neurons.
Brain 128, 18471854
145. Yang, Y. et al. (2004) Mutations in SCN9A, encoding a sodium
channel a subunit, in patients with primary erythermalgia. J. Med.
Genet. 41, 171174
146. Cummins, T.R. et al. (2004) Electrophysiological properties of
mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24, 82328236
147. Cregg, R. et al. (2013) Novel mutations mapping to the fourth
sodium channel domain of Nav1.7 result in variable clinical
manifestations of primary erythromelalgia. Neuromol. Med. 15,

166. Yang, S. et al. (2013) Discovery of a selective NaV1.7 inhibitor

from centipede venom with analgesic efcacy exceeding morphine in rodent pain models. Proc. Natl. Acad. Sci. U.S.A. 110,
167. Cardoso, F.C. et al. (2015) Identication and characterization of
ProTx-III [m-TRTX-Tp1a], a new voltage-gated sodium channel
inhibitor from venom of the tarantula Thrixopelma pruriens. Mol.
Pharmacol. 88, 291303
168. King, G.F. and Vetter, I. (2014) No gain, no pain: NaV1.7 as an
analgesic target. ACS Chem. Neurosci. 5, 749751
169. Dib-Hajj, S.D. et al. (2013) The NaV1.7 sodium channel: from
molecule to man. Nat. Rev. Neurosci. 14, 4962
170. Bagal, S.K. et al. (2014) Recent progress in sodium channel
modulators for pain. Bioorg. Med. Chem. Lett. 24, 36903699
171. Bagal, S.K. et al. (2015) Voltage gated sodium channels as drug
discovery targets. Channels (Austin) 9, 360366
172. Goldberg, Y.P. et al. (2012) Treatment of Nav1.7-mediated pain
in inherited erythromelalgia using a novel sodium channel
blocker. Pain 153, 8085

148. van Genderen, P.J. et al. (1993) Hereditary erythermalgia and

acquired erythromelalgia. Am. J. Med. Genet. 45, 530532

173. Han, C. et al. (2016) Sodium channel NaV1.8: emerging links to

human disease. Neurology 86, 473483

149. Faber, C.G. et al. (2012) Gain of function Nav1.7 mutations in

idiopathic small ber neuropathy. Ann. Neurol. 71, 2639

174. Jarvis, M.F. et al. (2007) A-803467, a potent and selective

Nav1.8 sodium channel blocker, attenuates neuropathic and
inammatory pain in the rat. Proc. Natl. Acad. Sci. U.S.A. 104,

150. Hoeijmakers, J.G. et al. (2012) Small-bre neuropathiesadvances in diagnosis, pathophysiology and management. Nat. Rev.
Neurol. 8, 369379
151. Huang, Y. et al. (2014) The role of TNF-alpha/NF-kappa B
pathway on the up-regulation of voltage-gated sodium channel
Nav1.7 in DRG neurons of rats with diabetic neuropathy. Neurochem. Int. 75, 112119
152. Hoeijmakers, J.G. et al. (2014) Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?
Trends Mol. Med. 20, 544550
153. Faber, C.G. et al. (2012) Gain-of-function Nav1.8 mutations
in painful neuropathy. Proc. Natl. Acad. Sci. U.S.A. 109,

175. Kort, M.E. et al. (2010) Subtype-selective Nav1.8 sodium channel

blockers: identication of potent, orally active nicotinamide derivatives. Bioorg. Med. Chem. Lett. 20, 68126815
176. Kort, M.E. et al. (2008) Discovery and biological evaluation of 5aryl-2-furfuramides, potent and selective blockers of the Nav1.8
sodium channel with efcacy in models of neuropathic and
inammatory pain. J. Med. Chem. 51, 407416
177. McGaraughty, S. et al. (2008) A selective Nav1.8 sodium channel
blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)
furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J. Pharmacol. Exp. Ther. 324, 12041211

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy


TIPS 1334 No. of Pages 21

178. Scanio, M.J. et al. (2010) Discovery and biological evaluation of

potent, selective, orally bioavailable, pyrazine-based blockers of
the Nav1.8 sodium channel with efcacy in a model of neuropathic pain. Bioorg. Med. Chem. 18, 78167825
179. Bagal, S.K. et al. (2015) Discovery and optimization of selective
Nav1.8 modulator series that demonstrate efcacy in preclinical
models of pain. ACS Med. Chem. Lett. 6, 650654
180. Payne, C.E. et al. (2015) A novel selective and orally bioavailable
Na 1.8 blocker PF-01247324 attenuates nociception and sensory neuron excitability. Br. J. Pharmacol. 172, 26542670
181. Zhang, X.F. et al. (2010) A-887826 is a structurally novel, potent
and voltage-dependent Nav1.8 sodium channel blocker that
attenuates neuropathic tactile allodynia in rats. Neuropharmacology 59, 201207
182. Bulaj, G. et al. (2006) Synthetic mO-conotoxin MrVIB blocks TTXresistant sodium channel NaV1.8 and has a long-lasting analgesic activity. Biochemistry 45, 74047414
183. Ekberg, J. et al. (2006) mO-conotoxin MrVIB selectively blocks
Nav1.8 sensory neuron specic sodium channels and
chronic pain behavior without motor decits. Proc. Natl. Acad.
Sci. U.S.A. 103, 1703017035
184. Gilchrist, J. and Bosmans, F. (2012) Animal toxins can alter the
function of Nav1.8 and Nav1.9. Toxins 4, 620632
185. Goral, R.O. et al. (2015) Heterologous expression of NaV1.9
chimeras in various cell systems. Pgers Arch. 467, 24232435
186. Weiser, T. (2006) Comparison of the effects of four Na+ channel
analgesics on TTX-resistant Na+ currents in rat sensory neurons
and recombinant Nav1.2 channels. Neurosci. Lett. 395, 179184
187. Wang, G.K. et al. (2004) Mexiletine block of wild-type and inactivation-decient human skeletal muscle hNav1.4 Na+ channels. J.
Physiol. 554, 621633
188. Shuraih, M. et al. (2007) A common SCN5A variant alters the
responsiveness of human sodium channels to class I antiarrhythmic agents. J. Cardiovasc. Electrophysiol. 18, 434440
189. Wu, M.T. et al. (2013) A novel SCN9A mutation responsible for
primary erythromelalgia and is resistant to the treatment of
sodium channel blockers. PLoS ONE 8, e55212
190. Tanelian, D.L. and Brose, W.G. (1991) Neuropathic pain can be
relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiology
74, 949951
191. Dejgard, A. et al. (1988) Mexiletine for treatment of chronic painful
diabetic neuropathy. Lancet 1, 911
192. Jang, H.S. et al. (2004) A case of primary erythromelalgia
improved by mexiletine. Br. J. Dermatol. 151, 708710

203. Orio, P. et al. (2009) Characteristics and physiological role of

hyperpolarization activated currents in mouse cold thermoreceptors. J. Physiol. 587, 19611976
204. Emery, E.C. et al. (2011) HCN2 ion channels play a central role in
inammatory and neuropathic pain. Science 333, 14621466
205. Qu, C. et al. (2011) Lesion of the rostral anterior cingulate cortex
eliminates the aversiveness of spontaneous neuropathic pain
following partial or complete axotomy. Pain 152, 16411648
206. Johansen, J.P. et al. (2001) The affective component of pain in
rodents: direct evidence for a contribution of the anterior cingulate cortex. Proc. Natl. Acad. Sci. U.S.A. 98, 80778082
207. King, T. et al. (2009) Unmasking the tonic-aversive state in
neuropathic pain. Nat. Neurosci. 12, 13641366
208. Colpaert, F.C. et al. (2001) Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. Pain 91, 3345
209. Martin, T.J. et al. (2007) Opioid self-administration in the nerveinjured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 106,
210. Sotocinal, S.G. et al. (2011) The Rat Grimace Scale: a partially
automated method for quantifying pain in the laboratory rat via
facial expressions. Mol. Pain 7, 55
211. Langford, D.J. et al. (2010) Coding of facial expressions of pain in
the laboratory mouse. Nat. Methods 7, 447449
212. Stevens, B. et al. (1996) Premature Infant Pain Prole: development and initial validation. Clin. J. Pain 12, 1322
213. Cobos, E.J. et al. (2012) Inammation-induced decrease in voluntary wheel running in mice: a nonreexive test for evaluating
inammatory pain and analgesia. Pain 153, 876884
214. Stevenson, G.W. et al. (2011) Monosodium iodoacetate-induced
osteoarthritis produces pain-depressed wheel running in rats:
implications for preclinical behavioral assessment of chronic pain.
Pharmacol. Biochem. Behav. 98, 3542
215. Andrews, N. et al. (2011) Novel, nonreex tests detect analgesic
action in rodents at clinically relevant concentrations. Ann. N. Y.
Acad. Sci. 1245, 1113
216. Jirkof, P. et al. (2010) Burrowing behavior as an indicator of postlaparotomy pain in mice. Front. Behav. Neurosci. 4, 165
217. Borszcz, G.S. (1995) Increases in vocalization and motor reex
thresholds are inuenced by the site of morphine microinjection:
comparisons following administration into the periaqueductal
gray, ventral medulla, and spinal subarachnoid space. Behav.
Neurosci. 109, 502522

193. Iqbal, J. et al. (2009) Experience with oral mexiletine in primary

erythromelalgia in children. Ann. Saudi Med. 29, 316318

218. Kurejova, M. et al. (2010) An improved behavioural assay demonstrates that ultrasound vocalizations constitute a reliable
indicator of chronic cancer pain and neuropathic pain. Mol.
Pain 6, 18

194. Choi, J.S. et al. (2009) Mexiletine-responsive erythromelalgia due

to a new Nav1.7 mutation showing use-dependent current falloff. Exp. Neurol. 216, 383389

219. Whiteside, G.T. et al. (2013) An industry perspective on the role

and utility of animal models of pain in drug discovery. Neurosci.
Lett. 557 (Part A), 6572

195. Meijer, I.A. et al. (2014) An atypical case of SCN9A mutation

presenting with global motor delay and a severe pain disorder.
Muscle Nerve 49, 134138

220. Finnerup, N.B. et al. (2015) Pharmacotherapy for neuropathic

pain in adults: a systematic review and meta-analysis. Lancet
Neurol. 14, 162173

196. Cregg, R. et al. (2014) Mexiletine as a treatment for primary

erythromelalgia: normalization of biophysical properties of
mutant L858F NaV 1.7 sodium channels. Br. J. Pharmacol.
171, 44554463

221. Dworkin, R.H. et al. (2012) Considerations for improving assay

sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153, 11481158

197. Drenth, J.P. et al. (2005) SCN9A mutations dene primary erythermalgia as a neuropathic disorder of voltage gated sodium
channels. J. Invest. Dermatol. 124, 13331338

222. Andersen, H.H. et al. (2014) MicroRNAs as modulators and

biomarkers of inammatory and neuropathic pain conditions.
Neurobiol. Dis. 71, 159168

198. Han, C. et al. (2006) Sporadic onset of erythermalgia: a gain-offunction mutation in Nav1.7. Ann. Neurol. 59, 553558

223. Carpenter, K.L. et al. (2015) Systemic, local, and imaging biomarkers of brain injury: more needed, and better use of those
already established? Front. Neurol. 6, 26

199. Borsook, D. et al. (2014) Lost but making progresswhere will

new analgesic drugs come from? Sci. Transl. Med. 6, 249sr243

224. Tracey, I. (2011) Can neuroimaging studies identify pain endophenotypes in humans? Nat. Rev. Neurol. 7, 173181

200. Dib-Hajj, S.D. and Waxman, S.G. (2014) Translational pain

research: lessons from genetics and genomics. Sci. Transl.
Med. 6, 249sr244

225. Hargreaves, R.J. et al. (2015) Optimizing central nervous system

drug development using molecular imaging. Clin. Pharmacol.
Ther. 98, 4760

201. Minett, M.S. et al. (2014) Signicant determinants of mouse pain

behaviour. PLoS ONE 9, e104458

226. Borsook, D. et al. (2008) A BOLD experiment in dening the

utility of fMRI in drug development. Neuroimage 42, 461466

202. Nassar, M.A. et al. (2005) Neuropathic pain develops normally in

mice lacking both Nav1.7 and Nav1.8. Mol. Pain 1, 24

227. Navratilova, E. and Porreca, F. (2014) Reward and motivation in

pain and pain relief. Nat. Neurosci. 17, 13041312


Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy

TIPS 1334 No. of Pages 21

228. Lai, H.C. and Jan, L.Y. (2006) The distribution and targeting of
neuronal voltage-gated ion channels. Nat. Rev. Neurosci. 7, 548562
229. Wu, J. et al. (2015) Structure of the voltage-gated calcium
channel Cav1.1 complex. Science 350, aad2395
230. Karmazinova, M. et al. (2010) Cysteines in the loop between IS5
and the pore helix of CaV3.1 are essential for channel gating.
Pgers Arch. 460, 10151028
231. Choe, W. et al. (2011) TTA-P2 is a potent and selective blocker of
T-type calcium channels in rat sensory neurons and a novel
antinociceptive agent. Mol. Pharmacol. 80, 900910
232. Francois, A. et al. (2013) State-dependent properties of a new Ttype calcium channel blocker enhance CaV3.2 selectivity and
support analgesic effects. Pain 154, 283293
233. Bladen, C. et al. (2015) Characterization of novel cannabinoid
based T-type calcium channel blockers with analgesic effects.
ACS Chem. Neurosci. 6, 277287
234. Lee, J.H. et al. (2014) Synthesis and biological evaluation of 1(isoxazol-5-ylmethylaminoethyl)-4-phenyl tetrahydropyridine and
piperidine derivatives as potent T-type calcium channel blockers
with antinociceptive effect in a neuropathic pain model. Eur. J.
Med. Chem. 74, 246257

235. Sali, A. and Blundell, T.L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234,
236. Long, S.B. et al. (2007) Atomic structure of a voltage-dependent
K+ channel in a lipid membrane-like environment. Nature 450,
237. Clayton, G.M. et al. (2008) Structure of the transmembrane
regions of a bacterial cyclic nucleotide-regulated channel. Proc.
Natl. Acad. Sci. U.S.A. 105, 15111515
238. Zagotta, W.N. et al. (2003) Structural basis for modulation and
agonist specicity of HCN pacemaker channels. Nature 425,
239. Santoro, B. and Tibbs, G.R. (1999) The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels. Ann. N. Y. Acad. Sci. 868, 741764
240. Catterall, W.A. and Swanson, T.M. (2015) Structural basis for
pharmacology of voltage-gated sodium and calcium channels.
Mol. Pharmacol. 88, 141150
241. Yang, Y. et al. (2012) Structural modelling and mutant cycle
analysis predict pharmacoresponsiveness of a NaV1.7 mutant
channel. Nat. Commun. 3, 1186

Trends in Pharmacological Sciences, Month Year, Vol. xx, No. yy